Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio10.10
Quick Ratio10.06
Price-To-Earnings
Trailing P/E Ratio-11.37
Forward P/E Ratio-16.04
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.61 million
Price / Sales1,626.77
Cash FlowN/A
Price / CashN/A
Book Value$8.68 per share
Price / Book9.83
Profitability
EPS (Most Recent Fiscal Year)($7.50)
Net Income$-302,130,000.00
Net MarginsN/A
Return on Equity-46.22%
Return on Assets-39.24%
Miscellaneous
Employees520
Outstanding Shares49,770,000
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced its quarterly earnings data on Monday, May, 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.81. The biopharmaceutical company had revenue of $10.68 million for the quarter, compared to analyst estimates of $56.58 million. During the same quarter in the previous year, the company earned ($1.63) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
20 equities research analysts have issued twelve-month target prices for Ultragenyx Pharmaceutical's stock. Their predictions range from $55.00 to $83.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $70.0556 in the next year. View Analyst Ratings for Ultragenyx Pharmaceutical.
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/30/2018)
- 2. JPMorgan Chase & Co. analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
- 3. Cowen Inc analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Nektar Therapeutics (NKTR), BeiGene (BGNE), Genmab A/S (GNMSF), Valeant Pharmaceuticals Intl (VRX), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT) and Dr.Reddy's Laboratories (RDY).
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
- Ms. Shalini Sharp, CFO & Exec. VP (Age 43)
- Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 58)
- Mr. John Richard Pinion II, Chief Quality Officer & Exec. VP of Translational Sciences (Age 52)
- Dr. Jayson Donald Alexander Dallas, Chief Commercial Officer & Exec. VP (Age 50)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
News coverage about RARE stock has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of 0.18 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.51%), Federated Investors Inc. PA (2.41%), Northern Trust Corp (1.04%), Millennium Management LLC (0.60%), Schwab Charles Investment Management Inc. (0.45%) and Rock Springs Capital Management LP (0.35%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which institutional investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including Legal & General Group Plc, Prudential Financial Inc., Point72 Asset Management L.P., Opaleye Management Inc., C WorldWide Group Holding A S, Smith Asset Management Group LP, Teacher Retirement System of Texas and California Public Employees Retirement System. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which institutional investors are buying Ultragenyx Pharmaceutical stock?
RARE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Federated Investors Inc. PA, UBS Group AG, Kornitzer Capital Management Inc. KS, Northern Trust Corp, Schwab Charles Investment Management Inc. and Highbridge Capital Management LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $85.31.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $3.93 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
